vs
Revvity（RVTY）与SELECTIVE INSURANCE GROUP INC（SIGI）财务数据对比。点击上方公司名可切换其他公司
SELECTIVE INSURANCE GROUP INC的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs 7.2%，领先5.6%），Revvity同比增速更快（5.9% vs 5.7%），过去两年Revvity的营收复合增速更高（9.0% vs 6.6%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
Selective保险集团是总部位于美国的保险控股企业，提供财产险、意外伤害险等多元保险产品，涵盖个人车险、住宅险、商业财产险、责任险、工伤补偿险等品类，主要服务美国境内的中小型企业、个人消费者及非营利组织，通过独立保险代理网络分销。
RVTY vs SIGI — 直观对比
营收规模更大
SIGI
是对方的1.8倍
$772.1M
营收增速更快
RVTY
高出0.1%
5.7%
净利率更高
RVTY
高出5.6%
7.2%
两年增速更快
RVTY
近两年复合增速
6.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $1.4B |
| 净利润 | $98.4M | $97.7M |
| 毛利率 | — | — |
| 营业利润率 | 14.5% | — |
| 净利率 | 12.7% | 7.2% |
| 营收同比 | 5.9% | 5.7% |
| 净利润同比 | 3.9% | -37.0% |
| 每股收益（稀释后） | $0.86 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYSIGI
| Q1 26 | — | $1.4B | ||
| Q4 25 | $772.1M | $1.4B | ||
| Q3 25 | $698.9M | $1.4B | ||
| Q2 25 | $720.3M | $1.3B | ||
| Q1 25 | $664.8M | $1.3B | ||
| Q4 24 | $729.4M | $1.3B | ||
| Q3 24 | $684.0M | $1.2B | ||
| Q2 24 | $691.7M | $1.2B |
净利润RVTYSIGI
| Q1 26 | — | $97.7M | ||
| Q4 25 | $98.4M | $155.2M | ||
| Q3 25 | $46.7M | $115.3M | ||
| Q2 25 | $53.9M | $85.9M | ||
| Q1 25 | $42.2M | $109.9M | ||
| Q4 24 | $94.6M | $95.5M | ||
| Q3 24 | $94.4M | $92.3M | ||
| Q2 24 | $55.4M | $-63.3M |
毛利率RVTYSIGI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 54.5% | — | ||
| Q1 25 | 56.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 55.7% | — |
营业利润率RVTYSIGI
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 14.4% | ||
| Q3 25 | 11.7% | 10.7% | ||
| Q2 25 | 12.6% | 8.2% | ||
| Q1 25 | 10.9% | 10.8% | ||
| Q4 24 | 16.3% | 9.5% | ||
| Q3 24 | 14.3% | 9.4% | ||
| Q2 24 | 12.4% | -6.7% |
净利率RVTYSIGI
| Q1 26 | — | 7.2% | ||
| Q4 25 | 12.7% | 11.4% | ||
| Q3 25 | 6.7% | 8.5% | ||
| Q2 25 | 7.5% | 6.5% | ||
| Q1 25 | 6.4% | 8.6% | ||
| Q4 24 | 13.0% | 7.6% | ||
| Q3 24 | 13.8% | 7.4% | ||
| Q2 24 | 8.0% | -5.3% |
每股收益（稀释后）RVTYSIGI
| Q1 26 | — | $1.58 | ||
| Q4 25 | $0.86 | $2.52 | ||
| Q3 25 | $0.40 | $1.85 | ||
| Q2 25 | $0.46 | $1.36 | ||
| Q1 25 | $0.35 | $1.76 | ||
| Q4 24 | $0.77 | $1.53 | ||
| Q3 24 | $0.77 | $1.47 | ||
| Q2 24 | $0.45 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $451.8M |
| 总债务越低越好 | — | $901.4M |
| 股东权益账面价值 | $7.3B | $3.6B |
| 总资产 | $12.2B | $15.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资RVTYSIGI
| Q1 26 | — | $451.8M | ||
| Q4 25 | $919.9M | — | ||
| Q3 25 | $931.4M | — | ||
| Q2 25 | $991.8M | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $2.0B | — |
总债务RVTYSIGI
| Q1 26 | — | $901.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $507.9M | ||
| Q3 24 | — | $508.2M | ||
| Q2 24 | — | $508.8M |
股东权益RVTYSIGI
| Q1 26 | — | $3.6B | ||
| Q4 25 | $7.3B | $3.6B | ||
| Q3 25 | $7.4B | $3.5B | ||
| Q2 25 | $7.6B | $3.4B | ||
| Q1 25 | $7.6B | $3.3B | ||
| Q4 24 | $7.7B | $3.1B | ||
| Q3 24 | $7.9B | $3.2B | ||
| Q2 24 | $7.9B | $2.9B |
总资产RVTYSIGI
| Q1 26 | — | $15.3B | ||
| Q4 25 | $12.2B | $15.2B | ||
| Q3 25 | $12.1B | $15.0B | ||
| Q2 25 | $12.4B | $14.5B | ||
| Q1 25 | $12.4B | $14.2B | ||
| Q4 24 | $12.4B | $13.5B | ||
| Q3 24 | $12.8B | $13.5B | ||
| Q2 24 | $13.4B | $12.6B |
负债/权益比RVTYSIGI
| Q1 26 | — | 0.25× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.17× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | — |
| 自由现金流经营现金流 - 资本支出 | $161.8M | — |
| 自由现金流率自由现金流/营收 | 21.0% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | — |
8季度趋势，按日历期对齐
经营现金流RVTYSIGI
| Q1 26 | — | — | ||
| Q4 25 | $182.0M | $376.3M | ||
| Q3 25 | $138.5M | $405.8M | ||
| Q2 25 | $134.3M | $166.9M | ||
| Q1 25 | $128.2M | $284.0M | ||
| Q4 24 | $174.2M | $332.2M | ||
| Q3 24 | $147.9M | $387.4M | ||
| Q2 24 | $158.6M | $266.1M |
自由现金流RVTYSIGI
| Q1 26 | — | — | ||
| Q4 25 | $161.8M | $366.3M | ||
| Q3 25 | $120.0M | $397.3M | ||
| Q2 25 | $115.5M | $159.7M | ||
| Q1 25 | $112.2M | $271.0M | ||
| Q4 24 | $149.8M | $324.7M | ||
| Q3 24 | $125.6M | $378.0M | ||
| Q2 24 | $136.6M | $258.4M |
自由现金流率RVTYSIGI
| Q1 26 | — | — | ||
| Q4 25 | 21.0% | 26.8% | ||
| Q3 25 | 17.2% | 29.2% | ||
| Q2 25 | 16.0% | 12.0% | ||
| Q1 25 | 16.9% | 21.1% | ||
| Q4 24 | 20.5% | 25.8% | ||
| Q3 24 | 18.4% | 30.4% | ||
| Q2 24 | 19.7% | 21.6% |
资本支出强度RVTYSIGI
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 0.7% | ||
| Q3 25 | 2.6% | 0.6% | ||
| Q2 25 | 2.6% | 0.5% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 3.4% | 0.6% | ||
| Q3 24 | 3.3% | 0.8% | ||
| Q2 24 | 3.2% | 0.6% |
现金转化率RVTYSIGI
| Q1 26 | — | — | ||
| Q4 25 | 1.85× | 2.42× | ||
| Q3 25 | 2.97× | 3.52× | ||
| Q2 25 | 2.49× | 1.94× | ||
| Q1 25 | 3.03× | 2.58× | ||
| Q4 24 | 1.84× | 3.48× | ||
| Q3 24 | 1.57× | 4.20× | ||
| Q2 24 | 2.87× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
SIGI
暂无分部数据
